>
Switch to:

Altamira Therapeutics Price-to-Tangible-Book

: 3.82 (As of Today)
View and export this data going back to 2014. Start your Free Trial

As of today (2021-10-19), Altamira Therapeutics's share price is $1.71. Altamira Therapeutics's Tangible Book per Share of Jun. 2021 for the quarter that ended in Jun. 2021 was $0.45. Hence, Altamira Therapeutics's Price to Tangible Book Ratio of today is 3.82.

The historical rank and industry rank for Altamira Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

NAS:CYTO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.13   Med: 3.67   Max: 140.31
Current: 3.8

2.13
140.31

During the past 10 years, Altamira Therapeutics's highest Price to Tangible Book Ratio was 140.31. The lowest was 2.13. And the median was 3.67.

NAS:CYTO's Price-to-Tangible-Book is ranked lower than
96% of the 250 Companies
in the Biotechnology industry.

( Industry Median: 4.88 vs. NAS:CYTO: 3.80 )

A closely related ratio is called PB Ratio. As of today, Altamira Therapeutics's share price is $1.71. Altamira Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2021 was $1.62. Hence, Altamira Therapeutics's P/B Ratio of today is 1.05.


Altamira Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Altamira Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.96 - 140.31 - 3.47

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 - - 3.47 7.97

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Price-to-Tangible-Book falls into.



Altamira Therapeutics Price-to-Tangible-Book Calculation

Altamira Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2021 )
=1.71/0.448
=3.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Altamira Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)